Rznomics Inc. (KOSDAQ:476830)
South Korea · Delayed Price · Currency is KRW 160,500
-1,500 (-0.93%)
At close: Dec 30, 2025
Rznomics Company Description
Rznomics Inc. develops RNA based gene therapies for cancers and intractable diseases.
Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma; RZ-001 (GBM) that is in Phase 1/2a stage for Glioblastoma; RZ-003, which is in discovery stage for Alzheimer; RZ-004, a pre-clinical product for Retinitis Pigmentosa; and RZ-005, a discovery stage product to treat Rett Syndrome.
Rznomics Inc. was incorporated in 2017 and is head quartered in Seongnam, South Korea.
Rznomics Inc.
| Country | South Korea |
| Founded | 2017 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Lee Seong-wook |
Contact Details
Address: #801 Innovalley Bldg. C Seongnam, 13486 South Korea | |
| Phone | 82 3 1706 8730 |
| Website | rznomics.com |
Stock Details
| Ticker Symbol | 476830 |
| Exchange | KOSDAQ |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Lee Seong-wook | Chief Executive Officer |
| Rim Jong-Sun | Chief Financial Officer |